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Abstract
Background: Plexin D1 is expressed on both tumor-associated endothelium and malignant cells
in a number of clinical brain tumors. Recently we demonstrated that Plexin D1 expression is
correlated with tumor invasion level and metastasis in a human melanoma progression series. The
objective of this study was to examine whether Plexin D1 might be clinically useful as a pan-tumor
vessel and pan-tumor cell target in solid tumors.
Methods: We examined Plexin D1 expression in clinical solid tumors (n = 77) of different origin,
a selection of pre-malignant lesions (n = 29) and a variety of non-tumor related tissues (n = 52) by
immunohistochemistry. Signals were verified in a selection of tissues via mRNA in situ hybridization.
Results: Plexin D1 is abundantly expressed on both activated established tumor vasculature and
malignant cells in the majority of primary and metastatic clinical tumors, as well as on macrophages
and fibroblasts. Importantly, in non-tumor related tissues Plexin D1 expression is restricted to a
subset of, presumably activated, fibroblasts and macrophages.
Conclusion: We demonstrate that Plexin D1 is in general ubiquitously expressed in tumor but
not normal vasculature, as well as in malignant cells in a wide range of human tissues. This
expression profile highlights Plexin D1 as a potentially valuable therapeutic target in clinical solid
tumors, enabling simultaneous targeting of different tumor compartments.
Background
Interference with a tumor's blood supply is an attractive
approach to inhibit tumor growth and dissemination.
Thereto, many research focused on targeting the ang-
iogenic process via inhibition of the Vascular endothelial
Growth Factor (VEGF-A) pathway. Despite promising
results in animal tumor models in which anti-VEGF ther-
apy translates into potent anti-tumor effects [1-3], imple-
mentation of these therapies for a number of tumor types
in the clinic has now learned that they, either or not in
combination with chemotherapy, do increase quality of
life or modestly prolong survival [4-7], but lack curative
effects [8,9]. This discrepancy may be partly due to the
high heterogeneity of the vasculature [10-12]: in estab-
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lished clinical tumors all possible maturation stages may
be represented, only a small fraction of which may be sus-
ceptible to VEGF inhibition [13]. This situation contrasts
that in fast growing animal tumors in which the entire
population of tumor vessels may be in a synchronized
maturation stage. In addition, we and others described
that in organs with intrinsically high vessel densities,
tumors and metastases are able to grow in an angiogen-
esis-independent fashion via co-option of pre-existing
blood vessels [14-18]. This provides tumors with a route
of escape which makes them (partially) unsusceptible to
anti-angiogenic compounds. Even more, anti-angiogen-
esis may drive a shift in brain tumors from an angiogenic
to a co-opting phenotype [19-21]. Therefore, vascular tar-
geting therapy in which the existing tumor vascular bed,
angiogenic or pre-existent, is attacked with the aim to
induce acute tumor-specific coagulation may be an attrac-
tive additional approach to deprive a tumor from blood
supply. To apply vascular targeting therapies, targetable
markers that discriminate tumor vessels from normal vas-
culature are needed. We previously described that Plexin
D1 (PLXND1) could be such a target [22].
PLXND1 belongs to a family of large transmembrane pro-
teins that are receptors for neuropilins and semaphorins
[23,24]. Plexins are involved in regulation of axonal pat-
terning during embryonic development [25-28]. Apart
from neuronal cells, PLXND1 is also expressed by vascular
endothelial cells during embryogenesis [29] and is of piv-
otal importance for vascular patterning, as illustrated by
the fact that PLXND1 knock-down in mice and zebrafish
results in abnormal development of the cardiovascular
system [30-32].
We previously demonstrated that PLXND1 is also specifi-
cally expressed on vascular endothelium during tumor-
associated angiogenesis in a mouse xenograft model of
cerebral melanoma metastasis and in a number of human
brain tumors, both of primary and metastatic origin [22].
Importantly, expression of this protein was also found on
tumor cells in these tumors [22], and this expression cor-
relates with malignancy grade in a human melanoma pro-
gression series: whereas PLXND1 is abundantly expressed
in both invasive primary and disseminated melanomas,
both in the vasculature and in tumor cells, its expression
was absent in benign melanocytic lesions and melanomas
in situ, except for expression on macrophages and fibrob-
lasts [33].
PLXND1 contains in its intracellular domain consensus
Rac/RhoA signalling motifs [29], suggestive of a role in
cytoskeletal rearrangements and cell motility, processes
which are fundamental for both tumor angiogenesis and
metastasis. PLXND1 may thus be functionally involved in
tumor development in multiple ways.
The expression profile of PLXND1 suggests that it may be
a valuable tumor target for established solid tumors,
allowing simultaneous targeting of different tumor com-
partments, i.e. vessels and tumor cells. To examine
whether PLXND1 might be clinically useful as a pan-
tumor vessel and pan-tumor cell target in solid tumors we
analyzed PLXND1 expression in a wide range of human
tumors of different origin, various pre-malignant and
non-tumor related tissues by immunohistochemistry and
mRNA in situ hybridization.
Methods
Tissue samples
Primary and metastatic tumor tissues of different origin (n
= 77), among them 15 paired samples of human primary
and metastatic lesions and various pre-malignant lesions
(n = 29), were selected from the archives of the Depart-
ment of Pathology and Radiology of the Radboud Univer-
sity Nijmegen Medical Centre. Furthermore, non-tumor
related tissues (n = 52) were obtained. The study was per-
formed according to the guidelines of the Code for proper
secondary use of human tissue in the Netherlands (Ver-
sion 2002, Federation of Biomedical Scientific Societies,
http://www.federa.org).
Immunohistochemistry
After deparaffinization and blocking of endogenous per-
oxidase activity, antigen retrieval was performed by treat-
ment with pronase according to standard protocols [33].
Non-specific binding sites were blocked by incubation
with 20% normal horse serum. Slides were incubated for
1 hr with single domain antibody A12, which was previ-
ously selected against a PLXND1-specific peptide [22].
A12 was detected by sequential incubations with the
mouse anti-VSV-G P5D4, biotinylated anti-mouse IgG
(Vector, Burlingame, CA), and avidin-biotin peroxidase
complex (Vector). Peroxidase was visualized by the 3-
amino-9-ethylcarbazole (ScyTek, Logan, UT) peroxidase
reaction, with haematoxylin as counterstain. All incuba-
tions were performed at room temperature. Blood vessel
origin was confirmed by endothelial stainings on serial
sections with anti-human CD31 antibody (DAKO, Glos-
trup, Denmark).
In a selection of tissues, macrophage identity was con-
firmed by double staining for PLXND1 and CD68. In
short, the above mentioned avidin-biotin peroxidase pro-
cedure was used to detect PLXND1 via rabbit anti-VSV-G
antiserum (Sigma Chemical Co., Zwijndrecht, The Neth-
erlands). Following visualization, avidin-biotin was
blocked according to standard protocols. Slides were suc-
cessively incubated with normal horse serum, mouse anti-
human CD68 antibody (DAKO) overnight at 4°C, bioti-
nylated anti-mouse IgG (Vector) and avidin-biotin alka-
line phosphatase (AP) complex (Vector) at RT. AP wasBMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
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visualized with a mixture of naphthol phosphate (Sigma),
levamisole (Sigma), and Fast Blue (Sigma).
PLXND1 mRNA In Situ Hybridization
To explore whether the PLXND1 transcript is also specifi-
cally present in malignant tissues, we performed mRNA in
situ hybridizations on 28 of the 158 paraffin-embedded
tissues analyzed by immunohistochemistry (malignant
lesions, n = 15; non-tumor related samples, n = 13) as pre-
viously described [22]. In brief, digoxigenin-labelled
sense and antisense human PLXND1 RNA probes, located
in the 3'-untranslated region, were generated by in vitro
transcription from a PLXND1 PCR product which was
flanked by T7 and T3 promoters as described [29]. Follow-
ing deparaffinization, 4 μm tumor sections were treated
with proteinase K (Roche, Almere, The Netherlands) at
37°C for 15 minutes and post-fixed in formaldehyde.
Non-specific binding sites were blocked by incubation
with acetic anhydride (Sigma) at room temperature. Tis-
sues were hybridized with digoxigenin-labelled RNA
probes at 63°C with 200 ng/ml probe. Single stranded
non-hybridized RNA was degraded with RNAse T1 (2
units/ml) at 37°C for 30 minutes. After subsequent pre-
incubation with normal sheep serum, the slides were
incubated with alkaline phosphatase-conjugated sheep
anti-digoxigenin antibody (Roche) at room temperature
for 1 hour. Alkaline phosphatase was visualized using
nitro blue tetrazolium (NBT; Roche) and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP; Roche) as substrate
with nuclear fast red as counterstain. Specificity of hybrid-
izations was verified by performing control hybridiza-
tions with sense probe.
Results
To explore whether PLXND1 may be clinically useful as a
pan-tumor endothelium and a pan-tumor cell target we
examined the expression profile of this protein in a large
variety of human tissue samples. As summarized in Table
1, PLXND1 is abundantly expressed in both the vascula-
ture and malignant cells in the majority of clinical tumors,
whereas in pre-malignant lesions the protein is present at
lower levels or, like in non-tumor related tissues, almost
completely absent (Table 2). Figure 1 shows vascular
(arrows) and tumor cell expression of PLXND1 in repre-
sentative samples of brain metastasis of adenocarcinoma
(A), glioblastoma multiforme (B), neuro-endocrine lung
tumor (C), ovarian adenocarcinoma (D), and prostatic
urothelial cell carcinoma (E). The insets in A and B show
corresponding in situ hybridization signals. Vascular and
tumor cell-associated PLXND1 expression was absent in 3
out of 5 medullary breast carcinomas, one out of 5 cervi-
cal squamous cell carcinomas, and all examined vulvar
squamous cell carcinomas (Table 1). A representative
sample of vulvar squamous cell carcinoma is shown in fig-
ure 1F. In addition, two low grade astrocytomas showed
infrequent vascular and tumor cell-associated PLXND1
expression (Table 1). As shown in figure 2A through F no
significant differences in staining pattern and intensity of
vascular structures (arrows) and malignant cells could be
observed between primary ductal breast carcinoma (A)
and a corresponding lymph node metastasis (B), colon
adenocarcinoma (C) and a corresponding liver metastasis
(D) and renal cell carcinoma (E) and a corresponding
brain metastasis (F, the inset shows corresponding in situ
hybridization signal).
To examine whether PLXND1 is expressed on angiogenic
vessels under physiological conditions, we also investi-
gated expression in endometrium. In 3 out of 5 prolifera-
tive phase endometria some vessels stained positive for
PLXND1 (Table 2). Figure 2G and 2H show lack of
PLXND1 protein and transcript (insets) in normal human
cerebral cortex and heart tissue. The granular staining pat-
tern in cerebral neurons (G) and cardiac myocytes (H) is
presumably due to aspecific binding of single domain
antibodies to lipofuscine as this is observed with other
non-related single domain antibodies too (not shown).
Apart from tumor-associated endothelium and tumor
cells, PLXND1 expression was also observed in subsets of
fibroblast- and macrophage-like cells in both tumor sam-
ples and pre-malignant and non-tumor related tissues.
Identity of macrophages was confirmed by double stain-
ing a selection of analyzed tissues for PLXND1 and CD68
(not shown).
Discussion
In previous work we showed that PLXND1 is expressed in
endothelial cells during developmental and tumor-associ-
ated angiogenesis [22,29]. Besides vascular expression,
high PLXND1 expression was also found on tumor cells in
cerebral melanoma metastases. Whereas a role of
PLXND1 in vessel patterning during development is well
established [30-32], the functional consequences of
PLXND1 expression on tumor cells and vessels are less
clear. We recently demonstrated that PLXND1 expression
is correlated with tumor invasion and metastasis in a
human melanoma progression series [33]. However, the
PLXND1 ligands Semaphorin 3E and 4A inhibit, rather
than promote, (tumor) angiogenesis [33,34]. Moreover,
Semaphorin 3E even exhibits anti-tumor and anti-meta-
static properties [33,35].
Here we show that PLXND1 is expressed at high levels on
activated established tumor vasculature in a variety of pri-
mary and metastatic human malignancies, whereas in
non-tumor related tissues PLXND1 expression is restricted
to a subset of, presumably activated, fibroblasts and mac-
rophages. These results are in agreement with our previ-
ous observations in clinical brain tumors of different
origin [22] and a series of cutaneous melanocytic lesionsBMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
Page 4 of 10
(page number not for citation purposes)
Table 1: Plexin D1 expression in solid malignancies.
Malignant tissue PLXND1 expression Remarks
Endothelial cells Tumor cells Subset of macrophages Subset of fibroblasts
Paired samples
Medullary breast carcinoma 
(n = 1)
- - + + Plasma cells also positive
Lymph node metastasis 
(n = 1)
Subset - + n.d.
Ductal breast carcinoma 
(n = 8)
+ + + + Some plasma cells also 
positive
Lymph node metastasis 
(n = 8)
++ + +
Adenocarcinoma of colon 
(n = 4)
++ + +
Liver metastasis (n = 4) + + + +
Alveolar soft part sarcoma of 
femur (n = 1)
+ + n.d. n.d.
Brain metastasis (n = 1) + + n.d. n.d.
Renal cell carcinoma (n = 1) + + n.d. n.d.
Brain metastasis (n = 1) + + n.d. n.d.
Non-paired samples
Adenocarcinoma of coecum 
(n = 1)
++ + -
Adenocarcinoma of 
oesophagus (n = 1)
++ + -
Adenocarcinoma of ovary 
(n = 1)
Subset + + +
Adenocarcinoma of prostate 
(n = 1)
++ - -BMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
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representing different stages of melanoma progression
[33]. So, for subsets of tumor types in which vessel activa-
tion has occurred, PLXND1 may be a valuable candidate
protein for vascular targeting approaches. Indeed, the
anti-PLXND1 single domain antibody A12 homes to and
accumulates in tumor vessels [22].
Successful vascular targeting has also been achieved with
agents directed against molecules of which expression is
restricted to vessels in early stages of angiogenesis. Exam-
ples are the L19 single chain antibody, directed against the
ED-B fragment of fibronectin which targets vasculature in
actively growing tumors [36], whereas this single chain
Adenocarcinoma of rectum 
(n = 5)
++ + +
Brain metastasis of 
adenocarcinoma (n = 4)
+ + n.d. n.d.
Liver metastasis of 
adenocarcinoma colon 
(n = 8)
++ + +
Ovary metastasis of 
adenocarcinoma colon 
(n = 1)
-+ - -
Low grade astrocytoma 
(n = 2)
Subset Subset n.d. n.d.
Glioblastoma Multiforme 
(n = 3)
+ + n.d. n.d.
Medulloblastoma (n = 1) + + n.d. n.d.
Neuro-endocrine tumor of 
lung (n = 2)
+ + + n.d.
Medullary breast carcinoma 
of (n = 4)
+ + + + 2 samples negative vessels 
and tumor cells
Lymph node metastasis of 
ductal breast carcinoma 
(n = 1)
Subset + - -
Squamous cell carcinoma of 
cervix (n = 5)
Subset + + - 1 sample negative vessels 
and tumor cells
Squamous cell carcinoma of 
vulva (n = 5)
-- + +
Urothelial cell carcinoma of 
prostate (n = 2)
++ + -
+, corresponding cell type expresses PLXND1
-, PLXND1 expression is absent in corresponding cell type
n.d., corresponding cell type is not detected
Table 1: Plexin D1 expression in solid malignancies. (Continued)BMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
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Table 2: Plexin D1 expression in pre-malignant and non-tumor related tissues.
Tissue PLXND1 expression Remarks
Endothelial cells Subsets of macrophages Subsets of fibroblasts
Pre-malignant samples
Ductal carcinoma in situ of breast 
(n = 5)
+ + + Weak staining of tumor cells
Lobular carcinoma in situ of breast 
(n = 3)
Weak + + Weak staining of tumor cells
Vulvar intraepithelial neoplasia 
(VIN)
Classic VIN III, HPV negative 
(n = 5)
-+ +
Classic VIN III, HPV positive 
(n = 8)
-+ +
Differentiated VIN III (n = 8) - + n.d.
Non-tumor related samples
Bladder (n = 1) - + -
Blood vessel
Atherosclerosis (n = 6) - + -
Fatty streaks (n = 1) - + -
Bone marrow (n = 2) n.d. - -
Brain
Cortex (n = 1) - n.d. n.d. Some neurons perinuclear staining
Alzheimer and CAA (n = 1) - n.d n.d.
Multiple Sclerosis (n = 2) - n.d n.d.
Breast
Normal breast (n = 2) - - - Some epithelial cells perinuclear 
staining
Ductal hyperplasia (n = 1) - + - Focal epithelial cells perinuclear 
staining
Endometrium
Proliferation phase (n = 5) Subset (n = 3) + n.d.BMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
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antibody is unable to detect quiescent endothelium in
low grade malignancies [37]. Targeted radiotherapy with
radiolabeled RGD peptides, recognizing integrin αvβ3 on
newly formed endothelial cells, led to reduced growth of
xenografts in mouse models of cancer [38-40]. Further-
more, chimeric proteins, consisting of antibodies against
the tumor vessel marker vascular cell adhesion molecule 1
(VCAM-1), fused to soluble Tissue Factor, induced tumor
specific blood clotting, tumor necrosis and growth delay
in different xenograft models [41].
Due to vessel heterogeneity in tumors [10-12,42] it is
unlikely that one single marker will behave as a targetable
pan-tumor-endothelial antigen, but appropriate mixtures
of different tumor vessel targeting agents, including anti-
PLXND1 antibodies, may allow specific targeting of the
majority of tumor vessels. For instance, to effectively
starve tumors like low grade gliomas, which (partly)
thrive on quiescent vasculature, targeting agents that rec-
ognize co-opted vessels in infiltrative tumor areas need to
be developed. It remains to be seen whether such targets
Secretion phase (n = 4) - + n.d.
Secretion/menstruation phase 
(n = 1)
-+ n . d .
Endometriosis interna (n = 1) - + n.d.
Heart (n = 1) - n.d n.d Myocytes perinuclear staining
Large intestine (n = 1) - + + Some epithelial cells perinuclear 
staining
Liver (n = 1) - + n.d. Some hepatocytes perinuclear 
staining
Lung (n = 2) - + n.d.
Oesophagus (n = 1) - + -
Pancreas (n = 1) - n.d n.d. Perinuclear staining Islets of 
Langerhans
Pituitary gland (n = 1) - n.d. n.d. Some epithelial cells perinuclear 
staining
Prostate (n = 1) - - n.d. Some epithelial cells perinuclear 
staining
Small intestine (n = 1) - + + Some epithelial cells perinuclear 
staining
Spleen (n = 1) - + n.d.
Thyroid gland (n = 1) - + n.d. Some epithelial cells perinuclear 
staining
Vulva
Normal vulva (n = 6) - + +
Lichen sclerosus (n = 6) - + +
+, corresponding cell type expresses PLXND1
-, PLXND1 expression is absent in corresponding cell type
n.d., corresponding cell type is not detected
Table 2: Plexin D1 expression in pre-malignant and non-tumor related tissues. (Continued)BMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
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can be identified and, if so, whether such strategy holds
promise for treatment of brain tumors, as it will include
some toxicity for interspersed normal brain in infiltrative
tumor areas.
Apart from vascular PLXND1 expression in tumors, the
protein is also abundantly expressed on tumor cells in a
wide range of clinical solid tumors which reinforces this
membrane protein as a tumor target, since it allows simul-
taneous targeting of different tumor compartments with
one compound. Since all tumor metastases tested, except
for one lymph node metastasis of a medullary breast car-
cinoma, expressed high levels of this protein, both on ves-
sels and tumor cells, a PLXND1-directed seek-and-destroy
strategy may therefore indeed be feasible.
Despite its abundant expression in many different tumor
types PLXND1 was not expressed on tumor cells and ves-
sels in a subset of medullary breast carcinomas. Interest-
ingly, these relatively rare tumors generally have a
favorable prognosis [43]. It is tempting to speculate that
PLXND1 expression is generally correlated with increased
malignancy grade. The only other tumor type in our series
which lacked vascular and tumor cell-associated PLXND1
PLXND1 expression in representative clinical tumor samples Figure 1
PLXND1 expression in representative clinical tumor 
samples. Immunohistochemical analyses using a single 
domain antibody against PLXND1 (Magnification ×200). 
PLXND1 is abundantly expressed in adenocarcinoma brain 
metastases (A), glioblastomas multiforme (B), neuro-endo-
crine lung tumors (C), an ovarian adenocarcinoma (D), and 
prostatic urothelial cell carcinomas (E). The arrows point at 
PLXND1-positive vasculature. PLXND1 is absent in both 
tumor vasculature (arrowheads) and tumor cells in vulvar 
squamous cell carcinomas (F). The insets in A and B show 
corresponding PLXND1 mRNA in situ hybridization analyses 
(Magnification ×200).
PLXND1 expression in representative clinical (tumor) sam- ples Figure 2
PLXND1 expression in representative clinical 
(tumor) samples. Immunohistochemical analyses using a 
single domain antibody against PLXND1 (Magnification 
×200). PLXND1 is expressed at high levels in primary ductal 
breast carcinomas (A) and corresponding lymph node metas-
tases (B), colon adenocarcinomas (C) and corresponding 
liver metastases (D) and a renal cell carcinoma (E) and corre-
sponding brain metastasis (F). The arrows point at PLXND1-
expressing tumor vessels. PLXND1 is not detected in normal 
human cerebral cortex (G) and heart (H) tissue samples. The 
insets in F, G and H show corresponding PLXND1 mRNA in 
situ hybridization analyses (Magnification ×200).BMC Cancer 2009, 9:297 http://www.biomedcentral.com/1471-2407/9/297
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expression was vulvar squamous cell carcinoma. Because
the increased microvessel density in these tumors suggests
angiogenesis [44], the lack of PLXND1 on vessels in these
tumors was unexpected [22]. Whether a lack of PLXND1
expression on these vessels is related to a more mature
state can only be speculated upon. Physiological angio-
genesis in proliferative phase endometria has been
described to occur mainly in a non-sprouting fashion via
vessel elongation [45] which may explain the appearance
of vascular PLXND1 in only a small subset of vessels in
such tissue.
Conclusion
We demonstrated that PLXND1 is in general ubiquitously
expressed in tumor but not normal vasculature, as well as
in malignant cells in a wide range of human (tumor) tis-
sues. This expression pattern warrants further investiga-
tion towards PLXND1 as a therapeutic target in oncology.
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